Prasugrel is a P2Y12 platelet inhibitor used to reduce risk of thrombotic cardiovascular events in unstable angina or non-ST-elevation myocardial infarction (NSTEMI), and in patients with STEMI when managed with either primary or delayed PCI. Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine.
- Mechanism
- Curator reviewed
Prasugrel is an thienopyridine and a prodrug which inhibits ADP receptors by irreversibly acting on the P2Y12 receptor on platelets. The active metabolite of prasugrel prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. Prasugrel is proposed to have a similar mechanism of action to clopidogrel.
- Primary indication
- Indicated in combination with acetylsalicylic acid (ASA) to prevent atherothrombotic events in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI).Curator reviewed · 3 structured indications
- Formula / weight
- C20H20FNO3S · 373.441 g/mol (avg)
- First approval
- Canada, 2010 · United States, 2009 · European Union, 2016
- Code names
- CS-747 · LY-640315
- Brand names
Resolves to
DTGLZDAWLRGWQN-UHFFFAOYSA-NSMILESCC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1What you can answer from here — as of August 30, 2026
Which drugs share a target with Prasugrel, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account